menu
    • menu
    [{"orgOrder":0,"company":"Attgeno","sponsor":"Vinnova","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Attgeno","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Attgeno \/ Vinnova","highestDevelopmentStatusID":"7","companyTruncated":"Attgeno \/ Vinnova"},{"orgOrder":0,"company":"Attgeno","sponsor":"Aurevia","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nitrosooxypropanol","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Attgeno","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attgeno \/ Aurevia","highestDevelopmentStatusID":"8","companyTruncated":"Attgeno \/ Aurevia"},{"orgOrder":0,"company":"Attgeno","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitrosooxypropanol","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Attgeno","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attgeno \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Attgeno \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Attgeno

    Menu

    Attgeno

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Attgeno

                            Sweden arrow
                            SupplySide West
                            Not Confirmed

                            Attgeno

                            Sweden arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrosooxypropanol

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Aurevia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hyperten...

                            Details : Nitrosooxypropanol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension, Pulmonary.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 26, 2023

                            Lead Product(s) : Nitrosooxypropanol

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Aurevia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Attgeno

                            Sweden arrow
                            SupplySide West
                            Not Confirmed

                            Attgeno

                            Sweden arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrosooxypropanol

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-in-Human Study to Assess the Safety and Tolerability of PDNO

                            Details : Nitrosooxypropanol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension, Pulmonary.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 18, 2021

                            Lead Product(s) : Nitrosooxypropanol

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Attgeno

                            Sweden arrow
                            SupplySide West
                            Not Confirmed

                            Attgeno

                            Sweden arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Chloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Vinnova

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pul...

                            Details : Sodium Chloride is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hypertension, Pulmonary.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            May 13, 2021

                            Lead Product(s) : Sodium Chloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Vinnova

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth